Objective(s): The glycan shield of the HIV-1 envelope glycoprotein complex (Env), in particular the glycan at position 332 in gp120, is frequently targeted by broadly neutralizing antibodies (bNAbs) isolated from HIV-1-infected individuals. We investigated the role of the second amino acid position of the N332 glycosylation motif Asn-X-Ser in HIV-1 evolution and neutralization sensitivity.
Introduction
HIV-1 neutralization is dependent on the ability of antibodies to recognize their target, the functional envelope glycoprotein complex (Env). Functional Env consists of a trimer of heterodimers of the gp120 surface protein, noncovalently linked to the gp41 transmembrane protein [1] [2] [3] [4] . Glycans that are attached to potential N-linked glycosylation sites (PNGS) on Env compose approximately half of the molecular mass of the external Env domains and are important for protein folding, viral infectivity and, together with variable regions, for shielding of conserved domains from antibody attack [5] [6] [7] . Isolation and characterization of broadly neutralizing antibodies (bNAbs) from HIV-1-infected individuals resulted in the identification of at least five different target epitopes on Env [8] . Many bNAbs are glycan dependent, and in particular the glycan at position N332 in gp120 (HXB2 numbering) is frequently targeted by bNAbs, contributing to a 'supersite of vulnerability' on Env [9, 10] .
N-linked glycosylation occurs at Asn-X-Ser (NXS) and
Asn-X-Thr motifs (NXT), where X can be any amino acid except Pro. However, even when these conditions are met, glycan occupancy is not guaranteed. NXS motifs have a two to three-fold lower probability of becoming glycosylated compared with NXT motifs when ignoring which amino acid is present at the X position [11] [12] [13] . In particular in the context of NXS motifs the second position (the 'X') is an important factor in deciding whether a glycan will be attached or not [13] , providing a potential source of heterogeneity in glycan occupancy. Previously, we observed that the N332 glycosylation motif in early subtype B Envs from the Amsterdam Cohort Studies (ACS) on HIV infection and AIDS was either NLS or NIS, and the NLS motif was associated with the induction of bNAbs [14] . In the particular case when a Leu or Ile is present at the 'X' residue, (i.e. NLS and NIS) the probabilities are 0.43 and 0.86, respectively [13] . Considering that an NLS motif has a two-fold lower probability in becoming glycosylated compared with an NIS motif [13] , we conducted a more in-depth study in the role of the 'X' in the N332 NXS motif.
Methods
Neutralization sensitivity of viral variants with different probability of glycosylation A full-length molecular clone HIV-1 LAI was used as the basis for the introduction of env of an early virus isolated from ACS individual H19792 that harboured an NLS motif ( [15] ; termed 'wild-type' virus). Mutant viruses with an NIS, NVS, or NLT motif were generated using previously described methods [16] . Virus stocks were generated by transfecting HEK293T cells with 4-mg full-length plasmid, using the lipofectamine method [17] . The neutralization assay using multiple bNAbs was carried out as described previously [18] .
Sequences and sequence analysis
To calculate the relative frequencies of different PNGS motifs at positions 332-334 in subtype B-infected individuals, we analysed Env sequences obtained from ACS participants that have been described in earlier studies [14, [19] [20] [21] , and 625 clade B Env sequences derived from the Los Alamos Database (i.e. all clade B sequences that were deposited before 2012, one sequence per individual). Statistical analyses were performed using Graphpad Prism v5.01 (GraphPad Software, Inc., La Jolla, California, USA). Differences in the evolution of the probability of glycosylation (Pg) within individuals and population were compared using Wilcoxon matched paired t-tests and unpaired t-tests, respectively, and were considered statistically significant when P values were 0.05 or less. The Genbank accession numbers of the sequences used are: EU743973-EU744046, EU744055-EU744094, EU744097-EU744145, EU744147-EU744 175, GU455425, GU455427-GU455429, GU455431-GU455439, GU455441, GU455443-GU455461, GU45 5464-GU455472, GU455474-GU455493, GU455514-GU455517, GU455519-GU455520, GU455523, GU45 5525, HQ644787-HQ644794, HQ644796-HQ644886, HQ644906-HQ644949, HQ644954-HQ644998, HQ6 45007-HQ645012, JF910158-JF910162, JF910165-JF9 10171, JF910173-JF910174, JF910176-JF910183, JF91 0186-JF910202, JF910207-JF910209, JF910215-JF9102 21, JF910225, JF910238, JF910242-JF910244, JF9102 48-JF910250, JF910254, and JF910256-JF910267.
Ethics statement
The ACS on HIV infection and AIDS are conducted in accordance with the ethical principles set out in the declaration of Helsinki, and written consent was obtained prior to data collection. The study was approved by the Academic Medical Center's Institutional Medical Ethics Committee.
Results
Considering the important role of glycans in escaping NAb responses [8] , we were interested in whether the probability of glycan occupancy (Pg) at position 332 evolved over time within HIV-1-infected individuals. Pg was defined based on previous studies (NXT where X 6 ¼ P: Pg ¼ 1.0; NLS: Pg ¼ 0.43; NVS: Pg ¼ 0.79; NIS: Pg ¼ 0.86; and no PNGS: Pg ¼ 0 [11, 13] ). By comparing the first and last available Env sequences from 37 HIV-1-infected ACS participants (median follow-up: 8.3 years), we observed a statistically significant increase in the probability of N332 glycosylation over time (P ¼ 0.0009; Fig. 1a ). Thus, in 14 of the 37 studied participants the Pg at N332 was increased, in one individual it was marginally decreased (Pg: 0.86-0.83), whereas the Pg was unchanged in the remaining 22 individuals. In 11 of these 22 individuals the Pg was already high (i.e. Pg ! 0.86), providing little opportunity for a further increase. In 10 out of 22 participants harbouring an NLS motif in the first available Env sequence, we observed evolution toward a motif with a higher probability of glycosylation ( Fig. 1b ), whereas the reverse was not true for individuals who had an NIS motif at the first time point (data not shown).
Next, we investigated whether the probability of glycosylation at position N332 has changed over the course of the HIV-1 epidemic. We compared early Env sequences (within 1 year after seroconversion) from 31 historical and 21 contemporary seroconverters (samples obtained between 1985-1989 and 2003-2006 , respectively), all infected with subtype B in Amsterdam. We found a significant increase in the probability of glycosylation of the N332 motif (P ¼ 0.025, Fig. 1c ). Overall our data suggest that the N332 glycosylation motif evolves toward a higher probability of occupancy, not only within infected individuals but also during the epidemic at the population level, probably as a mechanism to escape from immune responses.
If the second position of the N332 NXS motif indeed affects the probability of glycan occupancy, then this should also affect neutralization by N332-directed bNAbs. To explore this, we introduced the env of an early virus isolated from ACS individual ACH19792 that harboured an NLS motif in the full-length molecular clone HIV-1 LAI ( [15] ; termed 'wild-type' virus). This isolate with low probability of N332 glycosylation (Pg ¼ 0.43) was previously shown to be resistant to both 2G12 and PGT126 [14] . We generated mutant viruses with an NIS (Pg ¼ 0.86), NVS (Pg ¼ 0.79), or NLT (Pg ¼ 1.0) motif. These mutations were chosen based on the enhanced probability of glycosylation and their presence in evolving ACS subtype B isolates and the evolution within ACH19792 (NLS toward NIS). The NIS and NVS mutant viruses were as infectious as the original wild-type virus, whereas the NLT mutant was not infectious at all (data not shown). This result is consistent with the virtual absence of NXT motifs at position 332 from HIV-1 subtype B Los Alamos sequences (Los Alamos Database; n ¼ 625; 1.4% NXT; 0.5% NLT; Fig. 1d ). The analysis of 625 subtype B sequences from the Los Alamos Database, revealed a high frequency of NXS motifs (84.4%), of which 92.4% were NLS or NIS motifs, in concordance with the glycosylation motifs in the ACS samples.
Next we tested neutralization sensitivity of the NLS (wild-type), NIS, and NVS virus variants to N332dependent bNAbs of the PGT121-family (PGT121-123), the PGT128-family (PGT125-PGT130), the PGT135-family (PGT135-136), and 2G12 (Table 1 ) [22] . VRC01 was included as a control. We observed that the mutant viruses, with a higher probability of N332 occupancy, were 4.3-fold (NIS) and 2.6-fold (NVS) more sensitive to PGT121 neutralization, whereas this difference was not observed for PGT122 and PGT123. The mutant viruses were also substantially more sensitive to PGT126 (44 and 48-fold, respectively), PGT128 (39 and 60-fold) and PGT130 (17 and 41-fold; Table 1 ). All three viruses were resistant to neutralization by PGT125, PGT127, PGT135, PGT136, and 2G12 at the bNAb concentrations tested here. Subtleties in the fine specificities and dependencies of the individual PGT121 and PGT128-family members are probably responsible for the observed differences between them [23] [24] [25] . VRC01 neutralization was minimally affected by the mutations. Overall, we found that neutralization by in particular PGT121, PGT126, PGT128, and PGT130 was affected by the second position of the N332 PNGS and, by inference, glycan occupancy at this site. Thus, the virus variants that had a high probability of glycan occupancy were more efficiently neutralized by these bNAbs.
Discussion
Our results highlight a previously unappreciated mechanism by which HIV-1 can modulate its protective glycan shield. The fact that we found the increase in probability of N332 glycan occupancy over time within infected individuals, but also at the population level over the course of 20 years of HIV epidemic suggests that it is a mechanism to escape from neutralization [8, 19, [26] [27] [28] [29] . Interestingly, we have shown that the presence of an NLS motif, and not an NIS motif, on early Envs was associated with the development of bNAbs, suggesting that glycan occupancy at this position is important for shielding of vulnerable regions [14] . Paradoxically, neutralization escape by increasing glycan density might actually contribute to the presentation of glycan-dependent bNAb epitopes. IC50 values for the N332-dependent bNAbs and VRC01, tested against the H19792 NLS (wild-type), NIS and NVS mutant viruses. N332-dependent bNAbs are grouped according to family; PGT121 (PGT121-123), PGT128 (PGT125-128 and PGT130); PGT135 (PGT135-136). The last two columns list the fold increase in neutralization sensitivity of the mutant viruses, NIS and NVS, compared to wild-type.
The effect of the 'X' in the N332 glycosylation motif, NXS, on sensitivity to N332 glycan-dependent bNAbs is probably not black and white. It is possible that some Env molecules on a virion or even within an individual trimer contain an N332 glycan, whereas others do not. Possibly, this source of heterogeneous glycan occupancy contributes to unusual neutralization curves, similar to what has been proposed for heterogeneous glycan composition [30] . The differences in neutralization sensitivity might also be explained by dependence of the antibodies for a specific amino acid at position 333 (the 'X'). However, the available crystal structures of gp120 or trimer with PGT121 and PGT128 do not show any contacts of the antibodies with residue 333 [22, 25, 31, 32] . Furthermore, the influence of residue 333 on N332 glycan occupancy is probably dependent on the context of the particular virus isolate, and/or subtype. Mutagenesis of the 'X' residue to all possible amino acids in the context of the JR-FL isolate revealed that many amino acids were not tolerated at this position (data not shown). Interestingly, we also found a very low frequency of NXT motifs at position 332 in 625 subtype B Env sequences derived from the Los Alamos Database. The underlying reason for this is unclear. In this context, we note that our results might be subtype specific. For example, in subtype A, C, and AE, many of the isolates have a PNGS at position 334. Furthermore, several evolutionary studies report a glycan shift from N332 to N334 in response to N332-directed NAbs [33, 34] .
Overall these results suggest an important role for the second position of the N332 glycosylation motif in modulating the sensitivity for bNAbs, especially for some of the PGT128 family members. Although the 'X' of many of the NXS motifs in Env is conserved (N156: X ¼ C; N197: X ¼ T; N262: X ¼ G; N616: X ¼ K), our findings might be relevant for other NXS PNGS. For example, the X position in the motif for the N611 glycan, which is important for binding of bNAb PGT151 to the gp120-gp41 interface [35, 36] , varies substantially between virus isolates, providing a source of glycan heterogeneity.
Why is an NXS preferred at position 332 over an NXT motif? One possibility could be that incomplete N332 occupancy has a replicative advantage for the virus. Another possibility is that the S is a critical amino acid for protein folding or function, or the T is disadvantageous. However, this would be surprising given that S and T are biochemically quite similar and that an N is, in fact, allowed at position 334 (in the context of a PNGS shift from N332 to N334). We also observed such as shift in four of our study participants (data not shown).
The observations that glycan-directed antibodies arise frequently and relatively early in infected individuals, and can protect against infection when passively administered, makes them attractive targets for Env-based immunogen design [37] [38] [39] . However, our results suggest that the exact sequence of the N332 glycosylation motif should be considered. For example, an immunogen with a low probability of N332 occupancy might be less efficient at inducing N332 glycan-directed bNAbs, but then again more efficient at presenting epitopes that are shielded by the N332 glycan. #918.66.628), a grant from the European Community's Sixth Framework Program 'European HIV Enterprise 
